Australia markets closed

Tonix Pharmaceuticals Holding Corp. (TPM.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
0.3800+0.0100 (+2.70%)
At close: 06:45PM CET

Tonix Pharmaceuticals Holding Corp.

26 Main Street
Suite 101
Chatham, NJ 07928
United States
862 799 8599
https://www.tonixpharma.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees73

Key executives

NameTitlePayExercisedYear born
Dr. Seth Lederman M.D.Co-Founder, Pres, CEO & Chairman1.18MN/A1958
Mr. Bradley Saenger CPA, CPACFO & Treasurer595kN/A1974
Dr. Gregory M. Sullivan M.D.Chief Medical Officer & Sec.616kN/A1966
Mrs. Jessica Edgar MorrisChief Operating OfficerN/AN/AN/A
Dr. Herbert W. Harris M.D., Ph.D.Exec. VP of Translational MedicineN/AN/AN/A
Dr. Bruce L. Daugherty M.B.A., Ph.D.Exec. VP of ResearchN/AN/A1958
Ms. Siobhan Fogarty B.Sc., M.Sc.Exec. VP of Product Devel.N/AN/AN/A
Dr. Darryl Rideout Ph.D.Exec. VP of Experimental ChemistryN/AN/AN/A
Dr. Sina Bavari Ph.D.Exec. VP of Infectious Disease R&DN/AN/AN/A
Dr. Daniel J. Clauw M.D.ConsultantN/AN/AN/A
Amounts are as of 31 December 2021, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The company's immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, including TNX-1500, a humanized monoclonal antibody targeting CD40-ligand being developed for the prevention of allograft and xenograft rejection and for the treatment of autoimmune diseases. Its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. The company's infectious disease pipeline includes TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. Its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication. The company was founded in 2007 and is headquartered in Chatham, New Jersey.

Corporate governance

Tonix Pharmaceuticals Holding Corp.’s ISS governance QualityScore as of 28 November 2022 is 7. The pillar scores are Audit: 6; Board: 7; Shareholder rights: 5; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.